This marks our first recommendation specifically for previously untreated late-stage classical Hodgkin lymphoma and follows an improved confidential discount to the NHS on the treatment's list price ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage classical Hodgkin lymphoma, making it an option for around 800 people ...

Breakthrough for late-stage Hodgkin lymphoma: NICE has approved brentuximab vedotin combination therapy as the first treatment specifically for previously untreated stage 3 or 4 classical Hodgkin ...

Breakthrough for late-stage Hodgkin lymphoma: NICE has approved brentuximab vedotin combination therapy as the first treatment specifically for previously untreated stage 3 or 4 classical Hodgkin ...

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

regimen for advanced stage classical Hodgkin lymphoma in a phase 3 trial. Although the patient backgrounds were different, both the BrECADD and eBEACOPP regimens in this study showed better outcomes ...

Paige Sargent was diagnosed with Stage 4 Hodgkin's lymphoma at 16 ... taking lessons with Leslie Hewlett and we worked on my classical technique, doing baby bits of opera, while she helped ...

Checkmate 205/039–classical Hodgkin lymphoma In 2011, through a collaboration agreement with Ono Pharmaceutical Co., Bristol Myers Squibb expanded its territorial rights to develop and commercialize ...

This exciting development marks the first recommendation for previously untreated late-stage classical Hodgkin lymphoma. The news comes after Takeda, the company behind the treatment, offered an ...